全身性強皮症– tag –

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...

このページでは患者さん向けに、膠原病・自己免疫疾患とは何かについてわかりやすく説明します。 膠原病（自己免疫疾患）とは、その名の通り、自分の「免疫」が「自己」...

このページでは患者さん向けに、膠原病・自己免疫疾患とは何かについてわかりやすく説明します。 膠原病（自己免疫疾患）とは、その名の通り、自分の「免疫」が「自己」...

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...